2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit

With 9 preclinical candidates actively being studied and 21 clinical trials taking place, the Adenosine landscape is bubbling with activity! No stone is left unturned as CD73, CD39, A1AR, A2AR, and Interior adenosine pathways are exploited. The field is poised to leap on the momentum from clinical success at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit.

Returning as the premier event devoted to improving the efficacy of drugs that target the adenosine pathway, overcoming obstacles related to resistance and immunosuppression, and accelerating the translation of therapeutics into the clinic.

Join experts in adenosine, immune checkpoint, tumor microenvironment, immune-oncology, and second-generation IO as they learn how combination medicines might improve the effectiveness and potency of treatment.

With more speakers, content, and networking opportunities than ever before, don't miss this opportunity to overcome these obstacles and exploit the adenosine pathway's therapeutic and commercial potential.

URLs:
Website: https://go.evvnt.com/1590511-0?pid=10018
Tickets: https://go.evvnt.com/1590511-2?pid=10018
Brochure: https://go.evvnt.com/1590511-3?pid=10018

Venue details: Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States

Prices:
FULL PACKAGE: Conference + Workshop Day - Drug Developer: USD 4297.00,
Conference Only - Drug Developer: USD 2999.00,
FULL PACKAGE: Conference + Workshop Day - Academic: USD 3697.00,
Conference Only - Academic: USD 2599.00

Speakers: Sandro Santagata, Assistant Professor Pathology/Laboratory of Systems Pharmacology, Brigham and Women's Hospital at Harvard Medical School, Hongtao Lu, Chief Scientific Officer, Elpiscience, Alex Gaither, Vice president of Biology, Exscientia, Joanne Lager, Chief Medical Officer, iTeos Therapeutics, Simon Robson, Professor, Massachusetts General Hospital and Harvard Medical School, Jennifer Bailey Lundberg, Assistant Professor, McGovern Medical School, The University of Texas Health Science Center at Houston, Bin Zhang, Professor, Northwestern University Feinberg School of Medicine, Ming Wang, Founder and Chief Executive Officer, Phanes Therapeutics Inc., Ian Walters, Chief Executive Officer, Portage Biotech, Detlev Boisin, Professor, Rutgers University, Achim Moesta, Vice President and Head of Immunology and Translational Sciences, Trishula Therapeutics, John Stagg, Professor, University of Montreal, Gennady Yegtkin, Professor, University of Turku